BroadenBio Co., Ltd. (BroadenBio) recently announced the completion of PreA+ round of financing of tens of millions (CNY). The financing was led by the original shareholder Tao Capital, followed by Minkang Health Technology, and the original shareholder Lapam Capital continued to increase investment.

The funding will primarily be used for the Phase 1 clinical trial of the potentially Best-in-Class (BIC) investigational drug BB102. In addition, the investment will also be used in the development of international cutting-edge small molecule inhibitors of intracellular immune checkpoint, and the preclinical study of globally First-in-Class (FIC) small molecule drug candidates that play immune activation and tumor suppression dual functions, as well as establishing a top-level immunology and small molecule coupling technology platform.

"We are very grateful to all investors, to Lapam Capital and Tao Capital, the well-known investment institutions in the industry, for their long-term support and companionship," said Xingmin Zhang, M.D., Ph.D., founder and Chief Executive Officer of BroadenBio. "BroadenBio has always been adhering to the original intention of its establishment, Gathering Talents, For Innovation, applying our unique technology platforms in the discovery and development of FIC and BIC innovative drugs, benefiting human health with immune technology."

Since its foundation, the company’s R&D pipeline has covered various fields such as oncology, autoimmune disease, and infection. Characteristic technology platforms are becoming increasingly perfect, and the R&D center has begun to take shape.

About BroadenBio

Founded in 2018 by three experts with more than 20 years of experience in internationally renowned pharmaceutical companies, BroadenBio Co., Ltd. (BroadenBio) has received angel round investment from well-known investment institutions such as Lapam Capital and Tao Capital since its inception.

Oriented by unmet clinical needs, BroadenBio utilizes its unique technology platform and insists on discovering and developing innovative new drugs with commercial prospects in its field of expertise. BroadenBio has a rich R&D pipeline, with a number of independently developed innovative molecules entering the clinical stage.

Located in Beijing Yizhuang Biomedicine Park, BroadenBio has a R&D center of nearly 2000 m², including advanced laboratories of chemical synthesis, chemical process and analysis, cell biology and immune function testing. As a National High-Tech Enterprise, BroadenBio has technologies covering the fields of drug design and synthesis, process development, drug screening and evaluation (in vivo and in vitro), mechanism of action elucidation, translational medicine and others